Most cancer drugs that kill tumors also damage healthy tissue. That is not a flaw in the design — it is the fundamental problem that oncology has been trying to solve for decades. And it is the problem that Stipple Bio, a Cambridge-based biotechnology company that emerged from stealth this week with a heavily oversubscribed […]
Fifty million dollars is a serious amount of money for a company that started as a vaccine project in Harvard’s Innovation Lab. But then again, Ozempic is a serious amount of market — and Terrestrial Bio, the Boston-based company that just closed a $50 million Series C round, is betting it has figured out something
Thirty years is a long time to build something. VentureWell — the Massachusetts-based nonprofit that has funded, trained, and connected tens of thousands of science and technology entrepreneurs since 1995 — announced this week it is shutting down. The organization that helped launch student-founded companies across nearly 400 universities, that put $7 billion in investor
VentureWell Is Closing: It Took 30 Years to Build and a Stop-Work Order to End Read More »
Here is something worth sitting with for a moment. In 2025, Massachusetts startups raised $16.7 billion in venture capital. That is a 12% jump from 2024, the strongest gain since the pandemic. The state has more venture capital per capita than anywhere else in the country. And yet, by the standard metric everyone uses to
The Boston VC Ecosystem: How Venture Capital Actually Works in Massachusetts Read More »
In the high-stakes world of metabolic health, the next frontier isn’t a more effective injection—it’s a pill. As of late February 2026, two Boston-based startups, Vivtex and Nimbus Therapeutics, have emerged as the vanguard in the race to disrupt the $100 billion obesity market dominated by giants like Novo Nordisk and Eli Lilly. This week’s
